PRDS

NASDAQ

Pardes Biosciences Inc.

SectorHealth CareIndustry Medicinal Chemicals and Botanical Products IPO2021

$2.19+0.03 (+1.39%)

News25/Ratings3

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Latest news

25 items

956dSEC
SEC Form 15-12G filed by Pardes Biosciences Inc.
15-12G - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
966dSEC
SEC Form EFFECT filed by Pardes Biosciences Inc.
EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
966dSEC
SEC Form EFFECT filed by Pardes Biosciences Inc.
EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
966dINSIDER
SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
966d13D/G
SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
967dINSIDER
SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Varney Michael David closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4 filed by Smaldone Alsup Laurie
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4 filed by Pottage John C Jr
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Lopatin Uri A closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Lobell J Jay closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Lacy Elizabeth H. closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Henson Heidi closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4 filed by Hamill Laura
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4 filed by Autor Deborah M.
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dINSIDER
SEC Form 4: Auerbach Mark closing all direct ownership in the company
4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)
967dSEC
SEC Form 25-NSE filed by Pardes Biosciences Inc.
25-NSE - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
967dSEC
SEC Form S-8 POS filed by Pardes Biosciences Inc.
S-8 POS - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
967dSEC
SEC Form POS AM filed by Pardes Biosciences Inc.
POS AM - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
967dSEC
SEC Form POS AM filed by Pardes Biosciences Inc.
POS AM - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
967dSEC
Pardes Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
8-K - PARDES BIOSCIENCES, INC. (0001822711) (Filer)
967dSEC
SEC Form SC 13E3/A filed by Pardes Biosciences Inc. (Amendment)
SC 13E3/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
967dSEC
SEC Form SC 14D9/A filed by Pardes Biosciences Inc. (Amendment)
SC 14D9/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)
967dPR
Pardes Biosciences Announces Closing of Tender Offer
CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.
970dSEC
SEC Form SC 13E3/A filed by Pardes Biosciences Inc. (Amendment)
SC 13E3/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)